

- ture directions in the application of TIMP-2 and IGFBP7 in AKI clinical practice [J]. Clin Chem Lab Med, 2019, 57(5):567-576. DOI:10.1515/cclm-2018-0776.
- [19] Luthra A, Tyagi A. [TIMP-2]*[IGFBP7] for predicting early AKI [J]. Anaesth Crit Care Pain Med, 2019, 38(6):677. DOI: 10.1016/j.accpm.2018.11.011.
- [20] Adler C, Heller T, Schregel F, et al. TIMP-2/IGFBP7 predicts acute kidney injury in out-of-hospital cardiac arrest survivors [J]. Crit Care, 2018, 22(1):126. DOI: 10.1186/s13054-018-2042-9.
- [21] Liu C, Lu X, Mao Z, et al. The diagnostic accuracy of urinary [TIMP-2]*[IGFBP7] for acute kidney injury in adults: a PRISMA-compliant meta-analysis [J]. Medicine (Baltimore), 2017, 96(27):e7484. DOI: 10.1097/MD.0000000000007484.
- [22] Nalesso F, Cattarin L, Gobbi L, et al. Evaluating nephrocheck® as a predictive tool for acute kidney injury [J]. Int J Nephrol Renovasc Dis, 2020, 13: 85-96. DOI: 10.2147/IJNRD.S198222.
- [23] Kaczorowska A, Miękus N, Stefanowicz J, et al. Selected matrix metalloproteinases (MMP-2, MMP-7) and their inhibitor (TIMP-2) in adult and pediatric cancer [J]. Diagnostics (Basel), 2020, 10(8):547. DOI:10.3390/diagnostics10080547.
- [24] Wen X, Zhang J, Wan X, et al. Tissue inhibitor of metalloproteinases-2 mediates kidney injury during sepsis [J]. Nephron, 2020, 144(12):644-649. DOI: 10.1159/000511165.
- [25] Couloures KG, Marsenic O. Can we use tissue inhibitor metalloproteinase-2 and insulin-like growth factor binding protein-7 levels to predict acute kidney injury in neonate and infants undergoing cardiac surgery? [J]. Pediatr Crit Care Med, 2020, 21(6):593-594. DOI: 10.1097/PCC.0000000000002282.
- [26] Kureel J, John AA, Prakash R, et al. MiR 376c inhibits osteoblastogenesis by targeting Wnt3 and ARF-GEF-1 -facilitated augmentation of beta-catenin transactivation [J]. J Cell Biochem, 2018, 119(4):3293-3303. DOI: 10.1002/jcb.26490.
- [27] Watkins D, Zuhkle L, Engel M, et al. Sevenkey actions to eradicate rheumatic heart disease in Africa: the Addis Ababa communiqué [J]. Cardiovasc J Afr, 2016, 27(3):184-187. DOI: 10.5830/CVJA-2015-090.
- [28] Mendes RS, Martins G, Oliveira MV, et al. Iso-oncotic albumin mitigates brain and kidney injury in experimental focal ischemic stroke [J]. Front Neurol, 2020, 11:1001. DOI: 10.3389/fneur.2020.01001.
- [29] Carretero de la Encarnación B, Mateo Rodríguez E, Romero García CS, et al. Pulsed-Doppler evaluation of renal perfusion during pulsatile extracorporeal circulation. A pilot study [J]. Rev Esp Anestesiol Reanim, 2018, 65(7):380-384. DOI: 10.1016/j.redar.2018.01.014.
- [30] Wang X, Li Y, Zhao Z, et al. IGFBP7 regulates sepsis-induced epithelial-mesenchymal transition through ERK1/2 signaling [J]. Acta Biochim Biophys Sin (Shanghai), 2019, 51(8):799-806. DOI: 10.1093/abbs/gmz072.
- [31] Okyere P, Okyere I, Ndau TA, et al. Factors associated with acute kidney injury recovery in a tertiary hospital in Ghana: a prospective study [J]. Pan Afr Med J, 2019, 33:236. DOI: 10.11604/pamj.2019.33.236.15507.
- [32] Nel D, Poerstamper S, Verhage S, et al. Investigating the threshold for early renal allograft biopsy: a South African single-centre perspective [J]. S Afr Med J, 2020, 110(7):691-694. DOI: 10.7196/SAMJ.2020.v110i7.14483.
- [33] Wang Z, Shi C. Cellular senescence is a promising target for chronic wounds: a comprehensive review [J/OL]. Burns Trauma, 2020, 8: tkaa021 [2020-09-15]. <https://pubmed.ncbi.nlm.nih.gov/32607375/>. DOI: 10.1093/burnst/tkaa021.
- [34] Xu X, Gu S, Huang X, et al. The role of macrophages in the formation of hypertrophic scars and keloids [J/OL]. Burns Trauma, 2020, 8: tkaa006 [2020-09-15]. <https://pubmed.ncbi.nlm.nih.gov/32341919/>. DOI: 10.1093/burnst/tkaa006.
- [35] Leballo G, Chakane PM. Cardiac surgery-associated acute kidney injury: pathophysiology and diagnostic modalities and management [J]. Cardiovasc J Afr, 2020, 31(4):205-212. DOI: 10.5830/CVJA-2019-069.
- [36] Cabral L, Afreixo V, Meireles R, et al. Checking procalcitonin suitability for prognosis and antimicrobial therapy monitoring in burn patients [J]. Burns Trauma, 2018, 6:10 [2020-09-15]. <https://pubmed.ncbi.nlm.nih.gov/29610766/>. DOI: 10.1186/s41038-018-0112-5.

(收稿日期:2020-09-15)

· 科技快讯 ·

创伤治疗与康复的潜在治疗药物: 脱氢表雄酮

严重交通事故伤是 40 岁以下人群死亡的主要原因。内分泌、代谢和免疫系统均参与减轻组织损伤、启动创伤修复和再生的过程。然而, 不同年龄和性别的患者损伤应答和预后差异很大。作为损伤应答反应的一部分, 导致分解代谢和免疫抑制的糖皮质激素大量产生, 促进合成代谢和具有免疫增强作用的脱氢表雄酮 (DHEA) 及其代谢产物硫酸脱氢表雄酮 (DHEAS) 水平降低, 肾上腺类固醇生物合成增加。损伤后, 这些皮质醇的平衡影响患者预后, 高皮质醇与 DHEAS 比值与患病风险和病死率增加相关。创伤、脓毒症、创面愈合、神经保护及烧伤动物模型均显示补充 DHEAS 可下调炎症因子水平、提高生存率。已有研究显示恢复皮质醇与 DHEAS 比值可加速创面愈合和骨重构, 改善心情、增加幸福感。目前, 尚无 DHEA 或 DHEAS 用于创伤患者的研究, 本文综述了 DHEA 对严重创伤患者潜在的治疗和康复作用证据。

刘丹, 编译自《Burns Trauma》, 2019, 7:tkaa26; 刘琰, 审校